NOV 15, 2018 11:01 AM PST

A Subclass of Anti-Aging Compounds Serves as Alzheimer's Drug Candidates

WRITTEN BY: Nouran Amin

In a publication in Trends in Pharmacological Sciences, a subclass of anti-aging compounds, called geroneuroprotectors (GNPs), have been identified in research to hold a potential role in slowing the aging process in mice. Since aging is the greatest risk factor for Alzheimer's disease (AD)—GNPs mays serve as a potential drug candidate.

Credit: rdmag.com

Alzheimer’s disease is a progressive neurodegenerative disease that first deteriorates memory and thinking skills and, eventually, the ability to perform simple tasks. Although losing memory is common as people grow old, it is not considered a normal part of aging.

Watch a video about how Alzheimer's changes the brain:

"The argument for geroprotectors is that if one can extend the lifespan of model organisms, such as mice, and translate this effect to humans, then you should be able to slow down the appearance of many diseases that are associated with aging, such as Alzheimer's, Parkinson's, cancer and overall frailty," states Dave Schubert, first author, Salk Institute professor and head of Salk's Cellular Neurobiology Laboratory.

In the study researchers first focused on two medicinal properties found in plants fisetin, derived from fruits and vegetables, and curcumin, from the curry spice turmeric. Researchers used these compounds, to synthesize three AD drug candidates based on their ability to protect neurons from age-related toxicities in the brain. The compounds that were then synthesized are CMS121, CAD31, and J147.

"Since we found that the natural products curcumin and fisetin are also GNPs and commercially available as supplements, they could provide some therapeutic benefits right now," says Maher.

Credit: Clarke.edu

The lab has successfully shown that these synthetic compounds were able to reduce the molecular markers of aging. The researchers were able to examine that the molecular pathways associated with the AD drug candidates are the same as well-studied synthetic compounds previously shown to extend the lifespan of many animals.

Researchers are hoping to get two GNPs, CMS121 and J147, into clinical trials once FDA has approved. The study is believed to validate the drug discovery model in the promotion of healthy aging

"If these drugs have benefits for other body systems, such as maintaining kidney function and overall muscle health, they could be used in additional ways to treat or prevent the diseases of aging," Schubert says.

Source: Trends in Pharmacological Sciences, Salk Research Institute

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 22, 2019
Health & Medicine
NOV 22, 2019
Federal Government Weighs in on Marijuana and Opioid Addiction
The U.S. government is weighing in on the hot topic of whether or not medical marijuana is a successful tool in treating opioid addiction by barring the us...
NOV 24, 2019
Drug Discovery & Development
NOV 24, 2019
The unlikely pain killer
Pain can be anything a sunburn, a toothache, or a leg injury to name a few. The relievers that target our pain come in many colors—one being morphine...
DEC 09, 2019
Drug Discovery & Development
DEC 09, 2019
MagLev: Telling Drugs Apart
Likely, a suspicious powder will be composed of illicit drugs but nothing is certain until confirmation. To do so, analysis must be quick and efficient and...
JAN 18, 2020
Drug Discovery & Development
JAN 18, 2020
Drug Combo Targets Osteoarthritis
Individuals suffering from osteoarthritis often face challenges of limited treatment options mainly pain relievers or joint replacement surgery. However, s...
FEB 08, 2020
Cancer
FEB 08, 2020
Magic mushrooms help cancer patients' depression
A follow-up to a study originally published in the Journal of Psychopharmacology in 2016 reports the long-term benefits of a one-time, single-dose tre...
FEB 08, 2020
Drug Discovery & Development
FEB 08, 2020
Drug Targets Brain-Eating Amoebas
Brain-eating amoebas lead to high rates of mortality as a result of encephalitis. In fact, more than 95% of people who develop the infection will die. Unfo...
Loading Comments...